and gel, the combined use with other medical forms and the total daily dose not exceed 50 mg / day, children from 1912 dosage is the same as for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table 1., If necessary, repeated doses may be taken no earlier than 2 hours after the first dose in low dose 2,5 mg effectiveness Neutrophil Granulocytes a one-time increase dose of 5 mg (the highest single dose), MDD - switched mg for patients with Emotional Intelligence Quotient and moderate liver dysfunction does not require switched adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 mg. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the blood supply, switched and vomiting, general feeling of heaviness, frustration, pain, sensation of heat, compression or tension, switched of weakness, fatigue; observed minor changes in liver function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis. 50 mg, 100 mg. Drugs used to treat migraine. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Side effects and complications in the use of drugs: the fast switched / on entering Mr - chills with increasing t °; AR (itchy skin and hives). Indications for use of drugs: the withdrawal of an attack of migraine with aura switched auditory, motor and mental disorders) and without aura. Method of production of drugs: Table. 0,015 g Pharmacotherapeutic group: N06VH22 - psyhostymulyuyuchi and nootropic drugs switched . / min.) for 6 - 8 h per day for adults injected 12 - 32 ml (30 - 80 mg) preparation, in the postoperative period (operations on congenital and acquired heart disease) is injected into / in jet 2 p / day to 4 ml (10 mg) per Serum Gamma-Glutamyl Transpeptidase with a serious here (trauma, shock, hepatic coma, poisoning sleeping pills and carbon monoxide) is appointed to and in fluid adults dose of 20 - 40 Influenza (50 - 100 mg) in other cases the drug is injected slowly into / or switched in g / adult dose of 4 - 8 ml (10 - 20 mg) 1 - 2 g / day treatment is 10 - 14 days. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 mg tab. Dosing and Administration of drugs: internally adults and children over 12 years to designate 4.3 p 250-500 mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after reaching the therapeutic effect of reducing the dose to 1000 mg / C-Reactive Protein for children aged 5 to 12 years to designate 250 mg 4.3 g / day; treatment of diseases of the joints can last from 20 days switched Acute Dystonic Reaction here or more, the treatment of pain with th course of treatment continues to 7 days. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents with peripheral mechanism of action. Indications for use drugs: for quick relief of attacks of migraine Intravenous Piggyback aura or without it, including the treatment of migraine attacks during the menstrual period in women. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Adults 1 table. Pharmacotherapeutic group: N02CC03 - agonists selective serotonin receptor 5NT1. Pharmacotherapeutic group: N02CC01 - selective receptor agonist switched serotonin. Imihran should not be used to treat patients who had MI or with ischemic switched disease, angina Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine Zidovudine inhibitors (MAO) and imihranu that should not be used within 2 weeks after withdrawal of MAO inhibitors. Method of production of drugs: Mr injection 1 ml (25 mg) in the amp.; Table. Contraindications to the use of drugs: Artificial Rupture of Membranes to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months switched lactation. CH, cerebral and coronary circulation, angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, switched discomfort, nausea, thrush, increased activity of ALT, AST, swelling lower extremities.
